Both in Biotechnology
AIM ImmunoTech vs IN8bio
Over the past year AIM returned −91.5% and INAB returned −49.1%; their daily moves had a correlation of -0.04.
AIM −91.5% INAB −49.1%Growth of $1, one year, split-adjusted
| Metric | AIM | INAB |
|---|---|---|
| Price | $0.1521 | $0.8300 |
| Market cap | $6.1M | $8.2M |
| Today | −5.53% | −10.82% |
| 1 month | −16.8% | −40.7% |
| 6 months | −72.8% | −48.1% |
| Year to date | −86.5% | −64.5% |
| 1 year | −90.5% | −49.7% |
| Revenue growth (YoY) | +4.0% | — |
| Gross margin | 80.8% | — |
| Net margin | −26876.9% | — |
| P/E (TTM) | — | — |
| Price / sales | 63.9× | — |
| Net cash | $6.3M | $17.8M |
| Dividend yield | — | — |
| Volatility (60d) | 68.6% | 85.7% |
| Short % of float | 3.6% | 0.5% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).